Jupiter Life Line Hospitals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jupiter Life Line Hospitals reported its Q1 FY26 results on August 1, 2025, with both standalone and consolidated numbers reviewed by joint auditors (KKC & Associates LLP and Aswin P. Malde & Co) who issued an unmodified limited review report. Standalone revenue from operations grew ~15.6% year-on-year to ₹2,779.4 million (vs ₹2,404.7 million in Q1 FY25), while standalone net profit rose to ₹432.9 million (vs ₹406.5 million), translating to EPS of ₹6.60. On a consolidated basis, revenue from operations grew ~20.5% YoY to ₹3,476.3 million, though consolidated net profit was nearly flat at ₹438.8 million (vs ₹445.1 million) due to an exceptional loss of ₹33.3 million. The company recorded an exceptional loss of ₹14.1 million on a standalone basis as well. Results include contributions from subsidiaries and partnership firms in healthcare and hospitality segments.
Strong consolidated revenue growth above 20% signals healthy operational momentum, but the exceptional loss and slightly lower consolidated PAT may temper near-term sentiment. Standalone profit growth of ~6.5% and flat consolidated profit suggest margin pressure despite top-line expansion, warranting a close look at the full earnings call and segment details.